Elite in Prostate Cancer

Dr. Colleen F. Lawton

Radiation Oncology
9200 W Wisconsin Ave, Department Of Radiation Oncology, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Prostate Cancer
9200 W Wisconsin Ave, Department Of Radiation Oncology, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Colleen Lawton is a Radiation Oncologist in Milwaukee, Wisconsin. Dr. Lawton is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, and Prostatectomy.

Her clinical research consists of co-authoring 71 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 53 articles and participated in 7 clinical trials in the study of Prostate Cancer.

Specialties
Radiation Oncology
Licenses
Radiology in WI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

9200 W Wisconsin Ave, Department Of Radiation Oncology, Milwaukee, WI 53226
Other Locations
3200 Pleasant Valley Rd, West Bend, WI 53095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: July 16, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients
A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
View 9 Less Clinical Trials

71 Total Publications

Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy.
Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy.
Journal: International journal of radiation oncology, biology, physics
Published: April 08, 2025
Similar Doctors
Distinguished in Prostate Cancer
Dr. Parthiv S. Mehta
Radiation Oncology
Distinguished in Prostate Cancer
Dr. Parthiv S. Mehta
Radiation Oncology

Uropartners LLC

95 N Greenleaf St, Suite A, 
Gurnee, IL 
 (47.5 miles away)
847-623-4640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Parthiv Mehta is a Radiation Oncologist in Gurnee, Illinois. Dr. Mehta is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer and Familial Prostate Cancer. Dr. Mehta is currently accepting new patients.

Distinguished in Prostate Cancer
Dr. Wingate F. Clapper
Radiation Oncology
Distinguished in Prostate Cancer
Dr. Wingate F. Clapper
Radiation Oncology
N16w24131 Riverwood Drive, 
Waukesha, WI 
 (10.3 miles away)
262-696-0696
Languages Spoken:
English
See accepted insurances

Wingate Clapper is a Radiation Oncologist in Waukesha, Wisconsin. Dr. Clapper is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Oligodendroglioma, and Astrocytoma.

Ellen L. Ziaja
Distinguished in Prostate Cancer
Dr. Ellen L. Ziaja
Radiation Oncology
Distinguished in Prostate Cancer
Dr. Ellen L. Ziaja
Radiation Oncology

Aurora Radiation Oncology

36500 Aurora Dr, 
Summit, WI 
 (22.5 miles away)
262-434-1800
Languages Spoken:
English
See accepted insurances

Ellen Ziaja is a Radiation Oncologist in Summit, Wisconsin. Dr. Ziaja is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lawton's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile